Crizotinib (PF-02341066) is a potent c-Met and ALK inhibitor with IC50 of 11 nM and 24 nM, respectively, in cell trials. It is also a potent ROS1 inhibitor with a Ki value of less than 0.025 nM. Crizotinib induces autophagy in a variety of lung cancer cell lines by inhibiting the STAT3 pathway.

Brand: BCM

 

Target: ROS Kinase; ALK; Autophagy; c-Met/HGFR; ROS

 

Signaling Pathways: Angiogenesis; Autophagy; Immunology/Inflammation; Tyrosine Kinase/Adaptors

 

Melting Point: 192 °C

 

Boiling Point: 599.2±50.0 °C at 760 mmHg

 

Flashing Point: 316.2±30.1 °C

 

Vapour Pressure: 0.0±1.7 mmHg at 25°C

 

Solubility: Soluble in DMSO. Insoluble in Water; insoluble in Ethanol.

 

GHS: GHS07, GHS08, GHS09

 

Isomeric SMILES: C[C@H](C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N  

 

InChIKey: KTEIFNKAUNYNJU-GFCCVEGCSA-N  

 

InChI: InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1

 

Attribute
[Chem Name]	3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine
[Synonym]	Crizotinib; PF-02341066
[CAS No.]	877399-52-5
[EINECS]	638-814-9
[MDL No.]	MFCD12407409
[Formula]	C21H22Cl2FN5O
[Molecular]	450.34
[Form]	White to tan powder
[Storage]	Keep in dark place. Sealed in dry, 2-8°C

Goods Tag